InDex Pharmaceuticals, a Swedish pharmaceutical company, is dedicated to improving the lives of patients suffering from immunological disorders. With a mission to develop effective and safe drugs for diseases with high unmet medical needs, their current focus is on ulcerative colitis. Ulcerative colitis is a chronic inflammation of the large intestines that affects individuals of all ages.

InDex Pharmaceuticals' lead drug candidate for the treatment of ulcerative colitis is cobitolimod, which is in late-stage clinical development. It stands out as a new and unique drug with a local anti-inflammatory effect that can heal the large intestine and alleviate ulcerative colitis symptoms without causing serious side effects. Cobitolimod has the potential to significantly improve the quality of life for patients suffering from ulcerative colitis.

Based on its exceptional combination of efficacy and safety, cobitolimod has a promising market potential, with estimated annual sales reaching over USD 1 billion. Cobitolimod is part of InDex Pharmaceuticals' patent-protected technology platform of TLR9-agonists, known as DNA-based ImmunoModulatory Sequences (DIMS), which have the potential to treat multiple immunological diseases. Established in 2000, InDex Pharmaceuticals is located at the Karolinska Institutet Science Park in Stockholm.

The company has a strong investor base, including Linc AB, HBM Healthcare Investments, 4th AP Fund, and Handelsbanken fonder. InDex Pharmaceuticals Holding AB (publ) is the parent company of the Group, which includes InDex Pharmaceuticals AB and InDex Diagnostics AB, its wholly owned subsidiary